Industry experts gathered at the Meditech Stackathon 2024 to address import dependency in India’s MedTech sector. The event, hosted by the Department of Pharmaceuticals and the CII, aimed to slash imports from 75% to 50% within five years. Stakeholders discussed strategies for fostering self-reliance and enhancing the sector’s global competitiveness.
Strategic Policy Framework
Dr. Arunish Chawla, Secretary of the Department of Pharmaceuticals, underscored the critical role of the Meditech Stackathon 2024 in defining the future trajectory of India’s MedTech sector. He articulated a clear vision, stating, “Effective policy-making will set the foundation for MedTech for the next 10-15 years.” Dr. Chawla highlighted that the initiative is pivotal not just for immediate advancements but for long-term strategic positioning in global markets.
The primary aim articulated during his address is to substantially enhance India’s export capabilities while achieving a balanced import coverage ratio of 1.0. This means equilibrating the value of imports to that of exports, thus strengthening the nation’s economic independence in medical technologies.
With the Indian MedTech industry projected to grow to $50 billion by 2030, up from the current $14 billion, the policies and frameworks discussed and developed during the Stackathon are expected to catalyze and sustain this growth. Dr. Chawla’s insights emphasize the government’s commitment to not only bolstering domestic capabilities but also positioning India as a formidable player on the international stage.
From Planning to Impact
RP Singh, Joint Secretary of the Department of Pharmaceuticals, stressed the critical need to diminish India’s reliance on imported medical devices, given the increasing domestic demand.
He emphasized that the government is intent on transforming the MedTech industry into one that is more value-based and driven by innovation. This strategic pivot is essential not only for tapping into the full potential of the industry but also for significantly improving patient care across the nation.
Singh elaborated that fostering an environment where innovation thrives will lead to the development of high-quality, cost-effective medical solutions. This approach is vital for India to manage its healthcare needs effectively while reducing the burden of imports. By shifting focus towards a more value-driven model, the industry can achieve higher standards in patient care and enhance overall health system efficiency.
Collaborative Excellence and Market Potential
Himanshu Baid, Chairman of the CII National Medical Technology Forum, underscored the importance of enhanced collaboration across the MedTech industry to realize significant growth. He noted that India’s MedTech exports have already surpassed the $4 billion mark. Baid is optimistic about India’s potential, projecting that the nation could secure 10% of the global MedTech market share within the next ten years.
Baid emphasized that achieving such a goal requires a unified effort from all stakeholders within the industry. By working together, India can leverage its capabilities to expand its footprint in the global market. This collective push is crucial for accelerating growth and establishing India as a dominant player in the international MedTech landscape.
Data Collection and Regulatory Challenges
Enhancing data collection processes is crucial for pinpointing disparities in product usage and manufacturing within the MedTech sector. Despite India’s strong position as a major player in the global medical devices market, it continues to experience a substantial trade deficit. For the fiscal year 2022-23, the country recorded net imports amounting to $4,101 million, reflecting an import coverage ratio of merely 0.45. Addressing these gaps is vital for balancing trade and improving the overall health of the industry.
Future Directions and Support for MSMEs
The discussions at the event also concentrated on crafting policies and regulatory frameworks that are conducive to industry growth. Stakeholders are advocating for robust support mechanisms for micro, small, and medium enterprises (MSMEs) through targeted incentives and dedicated technology funds.
These strategic measures are designed to fully harness the capabilities of India’s MedTech sector, aiming to diminish its reliance on imports and boost domestic production. This approach is essential for fostering a self-sufficient industry that can meet local demands and compete on a global scale.
Also Read: Green Manufacturing in India’s Biotech Industry
Collaborative Efforts of DoP and CII in MedTech Sector
The Department of Pharmaceuticals (DoP), under the Ministry of Chemicals and Fertilizers, plays a pivotal role in shaping India’s pharmaceutical and medical devices sectors. Tasked with promoting the growth and development of these industries, the DoP focuses on policy formulation, regulatory improvements, and fostering a conducive environment for innovation and expansion. Its initiatives are crucial for enhancing India’s self-reliance in pharmaceutical production and medical technology.
Collaboratively, the Confederation of Indian Industry (CII) works closely with the DoP to drive the nation’s health sector towards global competitiveness. As a leading industry association, the CII mobilizes industry stakeholders, facilitates dialogue with the government, and helps implement strategic policies through its extensive network.
The CII’s National Medical Technology Forum exemplifies this effort, focusing on critical issues such as regulatory frameworks, market expansion, and technology adoption within the MedTech field. Together, the DoP and the CII aim to fortify India’s standing in the global market while supporting sustainable growth and innovation in the pharmaceutical and MedTech industries.